A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy

Simply Wall St.

11/19

Immunocore Holdings (NasdaqGS:IMCR) revealed promising Phase 1 results for its IMC-I109V therapy targeting hepatitis B. The treatment was generally well tolerated, with early data indicating ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584961046"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584961046\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584961046?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-11-19 03:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584961046","market":"hk","top_or_hot":-1,"title":"A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy","media":"Simply Wall St.","content":"<div>\n<p>Immunocore Holdings (NasdaqGS:IMCR) revealed promising Phase 1 results for its IMC-I109V therapy targeting hepatitis B. The treatment was generally well tolerated, with early data indicating ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/a-fresh-look-at-immunocore-holdings-nasdaqgsimcr-valuation-a\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2025-11-19 03:29</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Immunocore Holdings (NasdaqGS:IMCR) revealed promising Phase 1 results for its IMC-I109V therapy targeting hepatitis B. The treatment was generally well tolerated, with early data indicating ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/a-fresh-look-at-immunocore-holdings-nasdaqgsimcr-valuation-a\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/a-fresh-look-at-immunocore-holdings-nasdaqgsimcr-valuation-a\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/a-fresh-look-at-immunocore-holdings-nasdaqgsimcr-valuation-a","article_id":"2584961046","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/a-fresh-look-at-immunocore-holdings-nasdaqgsimcr-valuation-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584961046","pubTimestamp":1763494169,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immunocore Holdings (NasdaqGS:IMCR) revealed promising Phase 1 results for its IMC-I109V therapy targeting hepatitis B. The treatment was generally well tolerated, with early data indicating reductions in HBsAg, an encouraging signal for future development.\nSee our latest analysis for Immunocore Holdings.\nFollowing the promising Phase 1 results for IMC-I109V, Immunocore Holdings’ share price has jumped 8.97% over the past month. Enthusiasm around these clinical updates, along with recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"HBV治疗1期数据积极后重新审视Immunocore Holdings（纳斯达克GS：IMCR）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1.5},"content_text":"Immunocore Holdings (NasdaqGS:IMCR) revealed promising Phase 1 results for its IMC-I109V therapy targeting hepatitis B. The treatment was generally well tolerated, with early data indicating reductions in HBsAg, an encouraging signal for future development. See our latest analysis for Immunocore Holdings. Following the promising Phase 1 results for IMC-I109V, Immunocore Holdings’ share price has jumped 8.97% over the past month. Enthusiasm around these clinical updates, along with recent conference presentations and steady revenue growth, has helped the stock build momentum, as reflected in a strong 22.6% year-to-date share price return. While the one-year total shareholder return is 17.8%, long-term holders are still down from highs, as the three-year total return remains in negative territory. If innovative biotech milestones have you exploring the next big opportunity, consider expanding your search with the See the full list for free. With shares still trading at a significant discount to analyst price targets despite recent gains, the question now is whether Immunocore Holdings presents a compelling buying opportunity or if the market has already factored in future growth expectations. AdvertisementMost Popular Narrative: 41.2% Undervalued Immunocore Holdings is currently trading at $36.57, while the most widely followed narrative estimates its fair value at $62.20. This disconnect has sparked a heated debate over whether the recent price rally is just the beginning.  Momentum in pipeline diversification, progressing late-stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases, reduces single-product risk and sets the stage for multiple future revenue streams and earnings expansion.  Read the complete narrative. Curious what bold expectations drive this high price target? The narrative hinges on breakthrough therapies, market expansion, and a leap in profit margins usually reserved for industry leaders. Exactly what growth and profitability leap are analysts betting on? Get the details behind these provocative projections in the full narrative. Result: Fair Value of $62.20 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, ongoing reliance on KIMMTRAK and increasing R&D spending could slow growth if new pipeline therapies face setbacks. Find out about the key risks to this Immunocore Holdings narrative. Another View: Discounted Cash Flow Perspective While the analyst price target paints a bullish picture, our SWS DCF model offers a different perspective, estimating Immunocore Holdings' fair value at a remarkable $230.13. This assessment suggests the shares are trading at a significant discount. However, can the present fundamentals and pipeline support such an optimistic scenario? Look into how the SWS DCF model arrives at its fair value. IMCR Discounted Cash Flow as at Nov 2025 Build Your Own Immunocore Holdings Narrative If you think there's a different story to tell or want to dig into the numbers yourself, you can shape your own perspective in just a few minutes, so why not Do it your way A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Immunocore Holdings. Looking for More Investment Ideas? Don’t let great opportunities pass you by. The right screener can reveal hidden outperformers and transform the way you invest with confidence and clarity.  Target impressive yields and stable income streams by checking out these 18 dividend stocks with yields > 3% that consistently beat the market with strong payouts. Fuel your portfolio with innovation by tapping into these 27 AI penny stocks shaking up industries with real-world artificial intelligence breakthroughs. Seize unmatched value by scanning these 894 undervalued stocks based on cash flows that the market has yet to recognize, giving you a potential edge over the crowd.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}